{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:28:32Z","timestamp":1790310512473,"version":"4.1.0"},"reference-count":392,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The management of inflammatory bowel disease (IBD) in children and adolescents is challenging. Clear evidence-based guidelines are required for this population. This article provides recommendations for managing IBD in Saudi children and adolescents aged 6\u201319 years, developed by the Saudi Ministry of Health in collaboration with the Saudi Society of Clinical Pharmacy and the Saudi Gastroenterology Association. All 57 guideline statements are based on the most up-to-date information for the diagnosis and management of pediatric IBD.<\/jats:p>","DOI":"10.4103\/sjg.sjg_171_24","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T03:00:46Z","timestamp":1725073246000},"page":"107-136","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Saudi consensus guidance for the diagnosis and management of inflammatory bowel disease in children and adolescents"],"prefix":"10.4103","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3744-9907","authenticated-orcid":false,"given":"Omar I.","family":"Saadah","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Inflammatory Bowel Disease Unit, King Abdulaziz University Hospital, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0147-7540","authenticated-orcid":false,"given":"Turki","family":"AlAmeel","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Fahad Specialist Hospital, Dammam, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1424-5784","authenticated-orcid":false,"given":"Ahmed","family":"Al Sarkhy","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Pediatrics Department, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8434-2109","authenticated-orcid":false,"given":"Mohammed","family":"Hasosah","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Gastroenterology Unit, King Abdulaziz Medical City, National Guard Hospital, Jeddah, Saudi Arabia"},{"name":"Department of Pediatric Gastroenterology, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia"},{"name":"Department of Pediatric Gastroenterology, King Abdullah International Medical Research Center, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4512-9070","authenticated-orcid":false,"given":"Abdulrahman","family":"Al-Hussaini","sequence":"additional","affiliation":[{"name":"Children\u2019s Specialized Hospital, King Fahad Medical City, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9917-2758","authenticated-orcid":false,"given":"Majid A.","family":"Almadi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6102-9267","authenticated-orcid":false,"given":"Badr","family":"Al-Bawardy","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, Department of Internal Medicine, Section of Digestive Diseases, Yale School of Medicine, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0833-2945","authenticated-orcid":false,"given":"Talal A.","family":"Altuwaijri","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Vascular Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2967-4132","authenticated-orcid":false,"given":"Mohammed","family":"AlEdreesi","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Pediatric Department, Al Habib Medical Group, Khobar, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9079-1437","authenticated-orcid":false,"given":"Shakir A.","family":"Bakkari","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, King Saud Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1211-0157","authenticated-orcid":false,"given":"Othman R.","family":"Alharbi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2097-289X","authenticated-orcid":false,"given":"Nahla A.","family":"Azzam","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7000-2905","authenticated-orcid":false,"given":"Abdulelah","family":"Almutairdi","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Faisal Specialist Hospital and Research Center, Alfaisal University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1512-4332","authenticated-orcid":false,"given":"Khalidah A.","family":"Alenzi","sequence":"additional","affiliation":[{"name":"Executive Management of Transformation, Planning, and Business Development, Tabuk Health Cluster, Tabuk, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8441-4870","authenticated-orcid":false,"given":"Bedor A.","family":"Al-Omari","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care Services, Prince Sultan Military Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0985-6193","authenticated-orcid":false,"given":"Hajer Y.","family":"Almudaiheem","sequence":"additional","affiliation":[{"name":"Deputyship of Therapeutic Affairs, Ministry of Health, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-9086","authenticated-orcid":false,"given":"Ahmed H.","family":"Al-Jedai","sequence":"additional","affiliation":[{"name":"Deputyship of Therapeutic Affairs, Ministry of Health, Riyadh, Saudi Arabia"},{"name":"Colleges of Medicine and Pharmacy, Alfaisal University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6975-1297","authenticated-orcid":false,"given":"Mahmoud H.","family":"Mosli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Abdulaziz University, Inflammatory Bowel Disease Unit, King Abdulaziz University Hospital, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"R1-20250519","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/20469047.2019.1575056","article-title":"Paediatric inflammatory bowel disease:Review with a focus on practice in low- to middle-income countries","volume":"39","author":"Dalzell","year":"2019","journal-title":"Paediatr Int Child Health"},{"key":"R2-20250519","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/ecco-jcc\/jjaa037","article-title":"A systematic review and meta-analysis of paediatric inflammatory bowel disease incidence and prevalence across Europe","volume":"14","author":"Roberts","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"(Suppl 1)","key":"R3-20250519","first-page":"1","article-title":"Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease","volume":"29","author":"Mosli","year":"2022","journal-title":"Saudi J Gastroenterol"},{"key":"R4-20250519","first-page":"izad218","article-title":"Outcome of very early onset inflammatory bowel disease associated with primary sclerosing cholangitis: A Multicenter Study From the Pediatric IBD Porto Group of ESPGHAN","author":"Catassi","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"R5-20250519","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/MPG.0000000000002141","article-title":"Use of biosimilars in pediatric inflammatory bowel disease:An updated position statement of the pediatric IBD Porto Group of ESPGHAN","volume":"68","author":"De Ridder","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R6-20250519","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/ecco-jcc\/jjaa161","article-title":"The medical management of paediatric Crohn's disease: An ECCO-ESPGHAN guideline Update","volume":"15","author":"Van Rheenen","year":"2020","journal-title":"J Crohns Colitis"},{"key":"R7-20250519","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1053\/j.gastro.2019.03.022","article-title":"Canadian association of gastroenterology clinical practice guideline for the medical management of pediatric luminal Crohn's disease","volume":"157","author":"Mack","year":"2019","journal-title":"Gastroenterology"},{"key":"R8-20250519","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/MPG.0000000000002035","article-title":"Management of paediatric ulcerative colitis, part 1:Ambulatory care-An evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition","volume":"67","author":"Turner","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R9-20250519","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR guideline for diagnostic assessment in IBD Part 1:Initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J Crohns Colitis"},{"key":"R10-20250519","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/ecco-jcc\/jjy114","article-title":"Ecco-esgar guideline for diagnostic assessment in ibd part 2:Ibd scores and general principles and technical aspects","volume":"13","author":"Sturm","year":"2019","journal-title":"J Crohns Colitis"},{"key":"R11-20250519","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/MPG.0000000000002567","article-title":"North American Society for pediatric gastroenterology, hepatology, and nutrition position paper on the evaluation and management for patients with very early-onset inflammatory bowel disease","volume":"70","author":"Kelsen","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R12-20250519","first-page":"jjae040","article-title":"Accuracy of information given by ChatGPT for patients with inflammatory Bowel disease in relation to ECCO guidelines","author":"Sciberras","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R13-20250519","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/jcpt.13368","article-title":"Evaluation of pharmacotherapy recommendations in guidelines for inflammatory bowel disease","volume":"46","author":"Wang","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"R14-20250519","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/00365521.2021.2022191","article-title":"Danish Society for Gastroenterology and Hepatology's clinical recommendations for colonoscopic surveillance for colorectal dysplasia and cancer in patients with inflammatory bowel disease","volume":"57","author":"Ward","year":"2022","journal-title":"Scand J Gastroenterol"},{"key":"R15-20250519","doi-asserted-by":"crossref","first-page":"164","DOI":"10.21037\/tau-20-1020","article-title":"Does inflammatory bowel disease increase the risk of lower urinary tract tumors:A meta-analysis","volume":"10","author":"Zhang","year":"2021","journal-title":"Transl Androl Urol"},{"key":"R16-20250519","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.3390\/diagnostics13132135","article-title":"A study of the epidemiology, clinical, and phenotypic characteristics of inflammatory bowel disease in the northen-central region of Saudi Arabia","volume":"13","author":"Al-Fawzan","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"R17-20250519","first-page":"423","article-title":"Presenting features of childhood-onset inflammatory bowel disease in the central region of Saudi Arabia","volume":"33","author":"El Mouzan","year":"2012","journal-title":"Saudi Med J"},{"key":"R18-20250519","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3748\/wjg.v26.i4.416","article-title":"Regional variation of pediatric inflammatory bowel disease in Saudi Arabia:Results from a multicenter study","volume":"26","author":"El Mouzan","year":"2020","journal-title":"World J Gastroenterol"},{"key":"R19-20250519","first-page":"651","article-title":"Pediatric inflammatory bowel disease in the western region of Saudi Arabia. A retrospective analysis","volume":"34","author":"Hasosah","year":"2013","journal-title":"Saudi Med J"},{"key":"R20-20250519","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ajg.2013.05.004","article-title":"Serological markers of inflammatory bowel disease in children from the Western region of Saudi Arabia","volume":"14","author":"Saadah","year":"2013","journal-title":"Arab J Gastroenterol"},{"key":"R21-20250519","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/jcp.2007.050138","article-title":"An audit of UK pathologists'use of the British Society of Gastroenterology guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease","volume":"60","author":"Feakins","year":"2007","journal-title":"J Clin Pathol"},{"key":"R22-20250519","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1093\/ecco-jcc\/jjx092","article-title":"Extra-intestinal manifestations at diagnosis in paediatric- and elderly-onset ulcerative colitis are associated with a more severe disease outcome: A population-based study","volume":"11","author":"Duricova","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R23-20250519","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/sjg.SJG_409_20","article-title":"Bacterial dysbiosis predicts the diagnosis of Crohn's disease in Saudi children","volume":"27","author":"El Mouzan","year":"2021","journal-title":"Saudi J Gastroenterol"},{"key":"R24-20250519","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00054725-200405000-00010","article-title":"Comparison of serological markers of inflammatory bowel disease with clinical diagnosis in children","volume":"10","author":"Gupta","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"R25-20250519","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S2468-1253(22)00337-5","article-title":"Genomic diagnosis and care co-ordination for monogenic inflammatory bowel disease in children and adults:Consensus guideline on behalf of the British Society of Gastroenterology and British Society of Paediatric Gastroenterology, Hepatology and Nutrition","volume":"8","author":"Kammermeier","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R26-20250519","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/MPG.0000000000000239","article-title":"ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents","volume":"58","author":"Levine","year":"2014","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R27-20250519","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/apt.13636","article-title":"The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity","volume":"44","author":"Diederen","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R28-20250519","doi-asserted-by":"crossref","first-page":"114510","DOI":"10.1016\/j.physbeh.2024.114510","article-title":"Associations between immune biomarkers and symptoms of anxiety, depression, and insomnia in paediatric inflammatory bowel disease: A preliminary longitudinal analysis","volume":"278","author":"Ballesio","year":"2024","journal-title":"Physiol Behav"},{"key":"R29-20250519","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijpam.2016.08.004","article-title":"Clinical presentation of inflammatory bowel disease in Saudi children (Single centre experience)","volume":"3","author":"Alreheili","year":"2016","journal-title":"Int J Pediatr Adolesc Med"},{"key":"R30-20250519","doi-asserted-by":"crossref","first-page":"e14023","DOI":"10.1111\/ijcp.14023","article-title":"Body composition profile of children and adolescent patients with inflammatory bowel disease","volume":"75","author":"Alsufyani","year":"2021","journal-title":"Int J Clin Pract"},{"key":"R31-20250519","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/apa.13017","article-title":"Presenting phenotype of paediatric inflammatory bowel disease in Wessex, Southern England 2010\u20132013","volume":"104","author":"Ashton","year":"2015","journal-title":"Acta Paediatr"},{"key":"R32-20250519","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.3748\/wjg.v21.i20.6101","article-title":"Surgical strategies in paediatric inflammatory bowel disease","volume":"21","author":"Baillie","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R33-20250519","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4103\/sjg.SJG_300_18","article-title":"Extraintestinal manifestations of pediatric inflammatory bowel disease in Saudi Arabia","volume":"24","author":"Al-Mendalawi","year":"2018","journal-title":"Saudi J Gastroenterol"},{"key":"R34-20250519","first-page":"257","article-title":"Diagnostic role of upper gastrointestinal endoscopy in pediatric inflammatory bowel disease","volume":"39","author":"Castellaneta","year":"2004","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R35-20250519","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.crohns.2011.06.013","article-title":"Upper gastrointestinal involvement in paediatric onset Crohn's disease:Prevalence and clinical implications","volume":"6","author":"Crocco","year":"2012","journal-title":"J Crohns Colitis"},{"key":"R36-20250519","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ibd.21409","article-title":"IBD Around the world: Comparing the epidemiology, diagnosis, and treatment: Proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meeting","volume":"17","author":"Baumgart","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"R37-20250519","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/j.1651-2227.2010.01731.x","article-title":"Recognition and treatment of genitourinary complications in paediatric Crohn's disease using Infliximab","volume":"99","author":"Afzal","year":"2010","journal-title":"Acta Paediatr"},{"key":"R38-20250519","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/apt.17161","article-title":"Transmural healing evaluated by magnetic resonance enterography in paediatric patients with Crohn's disease receiving maintenance treatment with biologics","volume":"56","author":"Choi","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"R39-20250519","first-page":"521","article-title":"The genetics and pathogenesis of inflammatory bowel disease","volume":"9","author":"Maria","year":"2013","journal-title":"Gastroenterol Hepatol"},{"key":"R40-20250519","doi-asserted-by":"crossref","first-page":"8201672","DOI":"10.1155\/2017\/8201672","article-title":"New frontiers in genetics, gut microbiota, and immunity:A Rosetta stone for the pathogenesis of inflammatory bowel disease","volume":"2017","author":"Zhou","year":"2017","journal-title":"Biomed Res Int"},{"key":"R41-20250519","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/MIB.0000000000000289","article-title":"Combinatorial effects of diet and genetics on inflammatory bowel disease pathogenesis","volume":"21","author":"Dixon","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"R42-20250519","doi-asserted-by":"crossref","first-page":"E22","DOI":"10.1136\/flgastro-2022-102120","article-title":"Epigenetics in IBD:A conceptual framework for disease pathogenesis","volume":"13","author":"Natasha","year":"2022","journal-title":"Frontline Gastroenterol"},{"key":"R43-20250519","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/17474124.2019.1574569","article-title":"Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis","volume":"13","author":"Greuter","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R44-20250519","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1136\/gutjnl-2012-303954","article-title":"Advances in inflammatory bowel disease pathogenesis:Linking host genetics and the microbiome","volume":"62","author":"Knights","year":"2013","journal-title":"Gut"},{"key":"R45-20250519","first-page":"946","article-title":"Genetic variants of DMBT1 and SFTPD and disease severity in paediatric inflammatory bowel disease-A Polish population-based study","volume":"8","author":"Glapa-Nowak","year":"2021","journal-title":"Children (Basel)"},{"key":"R46-20250519","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ibd.21283","article-title":"Genetics of childhood-onset inflammatory bowel disease","volume":"17","author":"Henderson","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"R47-20250519","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1080\/00365520212511","article-title":"Familial and sporadic inflammatory bowel disease:Comparison of clinical features and serological markers in a genetically homogeneous population","volume":"37","author":"Halme","year":"2002","journal-title":"Scand J Gastroenterol"},{"key":"R48-20250519","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrgastro.2014.141","article-title":"IBD. Specific genetic and microbial signature associated with paediatric ileal Crohn's disease","volume":"11","author":"Leake","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R49-20250519","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1586\/egh.09.45","article-title":"Genetics of inflammatory bowel disease: Implications for disease pathogenesis and natural history","volume":"3","author":"Lees","year":"2009","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R50-20250519","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev-pathol-012615-044152","article-title":"Genetics and pathogenesis of inflammatory bowel disease","volume":"11","author":"Liu","year":"2016","journal-title":"Annu Rev Pathol"},{"key":"R51-20250519","article-title":"Systematic meta-analyses and field synopsis of genetic and epigenetic studies in paediatric inflammatory bowel disease","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"R52-20250519","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/1753425917722206","article-title":"Immunopathophysiology of inflammatory bowel disease:How genetics link barrier dysfunction and innate immunity to inflammation","volume":"23","author":"Mehta","year":"2017","journal-title":"Innate Immun"},{"key":"R53-20250519","first-page":"749","article-title":"The value of serological and genetic markers in inflammatory bowel disease;Strength and weakness of the studies","volume":"95","author":"A S","year":"2003","journal-title":"Rev Esp Enferm Dig"},{"key":"R54-20250519","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/MEG.0000000000001619","article-title":"Environmental exposures and the risk of inflammatory bowel disease:A case-control study from Saudi Arabia","volume":"32","author":"Algethmi","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R55-20250519","first-page":"438","article-title":"Environmental risk factors for childhood inflammatory bowel diseases:A multicenter case-control study","volume":"9","author":"Hasosah","year":"2022","journal-title":"Children (Basel)"},{"key":"R56-20250519","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.crohns.2012.05.024","article-title":"Environmental factors and risk of developing paediatric inflammatory bowel disease -- A population based study 2007-2009","volume":"7","author":"Jakobsen","year":"2013","journal-title":"J Crohns Colitis"},{"key":"R57-20250519","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.3390\/nu14214598","article-title":"Dietary therapy to improve nutrition and gut health in paediatric Crohn's disease; A feasibility study","volume":"14","author":"Allen","year":"2022","journal-title":"Nutrients"},{"key":"R58-20250519","first-page":"e43970","article-title":"Challenges in managing paediatric Crohn's disease with Crohn's Disease Exclusion Diet (CDED):The first single-center study in the United Arab Emirates","volume":"15","author":"Alsarhan","year":"2023","journal-title":"Cureus"},{"key":"R59-20250519","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3390\/nu13041067","article-title":"Food and food groups in Inflammatory Bowel Disease (IBD): The design of the Groningen Anti-Inflammatory Diet (GrAID)","volume":"13","author":"Campmans-Kuijpers","year":"2021","journal-title":"Nutrients"},{"key":"R60-20250519","doi-asserted-by":"crossref","first-page":"E122","DOI":"10.1093\/ibd\/izac045","article-title":"Positive gluten sensitivity serologies and the impact of gluten-free diet in patients with IBD","volume":"28","author":"Dahar","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"R61-20250519","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4103\/sjg.SJG_619_16","article-title":"Pre-illness diet as risk factor in pediatric inflammatory bowel disease in Saudi Arabia","volume":"23","author":"El Mouzan","year":"2017","journal-title":"Saudi J Gastroenterol"},{"key":"R62-20250519","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.3748\/wjg.v19.i28.4447","article-title":"Interplay of autophagy and innate immunity in Crohn's disease: A key immunobiologic feature","volume":"19","author":"Muzes","year":"2013","journal-title":"World J Gastroenterol"},{"key":"R63-20250519","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1136\/gut.2008.152207","article-title":"Genetic variants in the autophagy pathway contribute to paediatric Crohn's disease","volume":"57","author":"Peterson","year":"2008","journal-title":"Gut"},{"key":"R64-20250519","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.dld.2014.02.016","article-title":"Autophagy genes variants and paediatric Crohn's disease phenotype: A single-centre experience","volume":"46","author":"Strisciuglio","year":"2014","journal-title":"Dig Liver Dis"},{"key":"R65-20250519","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4103\/sjg.sjg_368_22","article-title":"Composition of the gut microbiota in patients with inflammatory bowel disease in Saudi Arabia: A pilot study","volume":"29","author":"Al-Amrah","year":"2023","journal-title":"Saudi J Gastroenterol"},{"key":"R66-20250519","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22041623","article-title":"Impact of microbial metabolites on microbiota-gut-brain axis in inflammatory bowel disease","volume":"22","author":"Banfi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R67-20250519","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/ecco-jcc\/jjac032","article-title":"A microbial signature for paediatric perianal Crohn's disease","volume":"16","author":"Breton","year":"2022","journal-title":"J Crohns Colitis"},{"key":"R68-20250519","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1136\/gut.2005.078824","article-title":"Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease","volume":"55","author":"Conte","year":"2006","journal-title":"Gut"},{"key":"R69-20250519","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3390\/ijms19051399","article-title":"High-throughput sequencing of microRNAs in glucocorticoid sensitive paediatric inflammatory bowel disease patients","volume":"19","author":"De Iudicibus","year":"2018","journal-title":"Int J Mol Sci"},{"key":"R70-20250519","doi-asserted-by":"crossref","first-page":"e0197649","DOI":"10.1371\/journal.pone.0197649","article-title":"Variability of core microbiota in newly diagnosed treatment-na\u00efve paediatric inflammatory bowel disease patients","volume":"13","author":"De Meij","year":"2018","journal-title":"PLoS One"},{"key":"R71-20250519","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/ecco-jcc\/jjw197","article-title":"Fungal microbiota profile in newly diagnosed treatment-na\u00efve children with Crohn's disease","volume":"11","author":"El Mouzan","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R72-20250519","doi-asserted-by":"crossref","first-page":"5725442","DOI":"10.1155\/2022\/5725442","article-title":"Microbiome-metabolome analysis of the immune microenvironment of the cecal contents, soft feces, and hard feces of hyplus rabbits","volume":"2022","author":"Li","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"R73-20250519","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/00365521.2019.1644368","article-title":"The microbiome reflects diagnosis and predicts disease severity in paediatric onset inflammatory bowel disease","volume":"54","author":"Malham","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"R74-20250519","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/ecco-jcc\/jjv147","article-title":"Altered fecal microbiota in paediatric inflammatory bowel disease","volume":"9","author":"Maukonen","year":"2015","journal-title":"J Crohns Colitis"},{"key":"R75-20250519","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00248-021-01697-9","article-title":"Paediatric inflammatory bowel disease and its relationship with the microbiome","volume":"82","author":"Fitzgerald","year":"2021","journal-title":"Microb Ecol"},{"key":"R76-20250519","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3748\/wjg.v17.i5.557","article-title":"Intestinal microbiota in inflammatory bowel disease:Friend of foe?","volume":"17","author":"Fava","year":"2011","journal-title":"World J Gastroenterol"},{"key":"R77-20250519","doi-asserted-by":"crossref","first-page":"e15533","DOI":"10.1371\/journal.pone.0015533","article-title":"Serological markers for inflammatory bowel disease in AIDS patients with evidence of microbial translocation","volume":"5","author":"Kamat","year":"2010","journal-title":"PLoS One"},{"key":"R78-20250519","doi-asserted-by":"crossref","first-page":"1005842","DOI":"10.3389\/fmicb.2022.1005842","article-title":"Oral administration of live combined Bacillus subtilis and Enterococcus faecium alleviates colonic oxidative stress and inflammation in osteoarthritic rats by improving fecal microbiome metabolism and enhancing the colonic barrier","volume":"13","author":"Tang","year":"2022","journal-title":"Front Microbiol"},{"key":"R79-20250519","doi-asserted-by":"crossref","first-page":"1220976","DOI":"10.3389\/fped.2023.1220976","article-title":"A pilot study of the use of the oral and faecal microbiota for the diagnosis of ulcerative colitis and Crohn's disease in a paediatric population","volume":"11","author":"Monle\u00f3n-Getino","year":"2023","journal-title":"Front Pediatr"},{"key":"R80-20250519","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12950-021-00279-3","article-title":"Interleukin 10 and interleukin 10 receptor in paediatric inflammatory bowel disease: From bench to bedside lesson","volume":"18","author":"Krawiec","year":"2021","journal-title":"J Inflamm (Lond)"},{"key":"R81-20250519","doi-asserted-by":"crossref","first-page":"115949","DOI":"10.1016\/j.bcp.2023.115949","article-title":"Gut-brain axis interacts with immunomodulation in inflammatory bowel disease","volume":"219","author":"Ye","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"R82-20250519","first-page":"1085","article-title":"Incidence of pediatric inflammatory bowel disease in Saudi Arabia:A multicenter national study","volume":"20","author":"El Mouzan","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"R83-20250519","doi-asserted-by":"crossref","first-page":"276","DOI":"10.5144\/0256-4947.2012.276","article-title":"Inflammatory bowel disease in Saudi Arabia:A hospital-based clinical study of 312 patients","volume":"32","author":"Al Fadda","year":"2012","journal-title":"Ann Saudi Med"},{"key":"R84-20250519","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4103\/sjg.SJG_457_18","article-title":"Diagnostic delay of pediatric inflammatory bowel disease in Saudi Arabia","volume":"25","author":"El Mouzan","year":"2019","journal-title":"Saudi J Gastroenterol"},{"key":"R85-20250519","doi-asserted-by":"crossref","first-page":"305","DOI":"10.4103\/sjmms.sjmms_175_23","article-title":"Prevalence and risk factors of cytomegalovirus colitis in inflammatory bowel disease patients in Riyadh, Saudi Arabia:A tertiary center experience","volume":"11","author":"Alotaibi","year":"2023","journal-title":"Saudi J Med Med Sci"},{"key":"R86-20250519","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4103\/sjg.sjg_3_23","article-title":"IBD-Disk as a tool estimating the prevalence of inflammatory bowel disease-related disability and associated influencing factors in Saudi Arabia: A cross-sectional study","volume":"29","author":"Meeralam","year":"2023","journal-title":"Saudi J Gastroenterol"},{"key":"R87-20250519","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1080\/13696998.2020.1791889","article-title":"The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia","volume":"23","author":"AlRuthia","year":"2020","journal-title":"J Med Econ"},{"key":"R88-20250519","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12962-019-0194-3","article-title":"Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia","volume":"17","author":"Alruthia","year":"2019","journal-title":"Cost Eff Resour Alloc"},{"key":"R89-20250519","doi-asserted-by":"crossref","first-page":"386","DOI":"10.5144\/0256-4947.2023.386","article-title":"Surgical outcomes and stoma-related complications in inflammatory bowel disease in Saudi Arabia:A retrospective study","volume":"43","author":"Bin Traiki","year":"2023","journal-title":"Ann Saudi Med"},{"key":"R90-20250519","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ajg.2020.07.002","article-title":"Prevalence of nutritional disorders in Saudi children with inflammatory bowel disease based on the national growth reference","volume":"21","author":"El Mouzan","year":"2020","journal-title":"Arab J Gastroenterol"},{"key":"R91-20250519","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/MPG.0b013e31805563f3","article-title":"Differentiating ulcerative colitis from Crohn disease in children and young adults:Report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America","volume":"44","author":"Bousvaros","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R92-20250519","first-page":"CR572","article-title":"Electric activity of the gut in ulcerative colitis and Crohn's disease:Electromyography as a tool for differentiating between the two conditions in the early stage","volume":"10","author":"Shafik","year":"2004","journal-title":"Med Sci Monit"},{"key":"R93-20250519","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/gut.43.3.310","article-title":"Differentiating ulcerative colitis from Crohn's disease:False dawn for CD44","volume":"43","author":"Spencer","year":"1998","journal-title":"Gut"},{"key":"R94-20250519","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/archdischild-2013-305512","article-title":"Ulcerative colitis:Management in adults, children and young people (NICE Clinical Guideline CG166)","volume":"99","author":"Stenke","year":"2014","journal-title":"Arch Dis Child Educ Pract Ed"},{"issue":"(8 Suppl 4)","key":"R95-20250519","first-page":"1","article-title":"A special meeting review edition: Clinical research highlights in IBD: Diagnosis and anti-tumor necrosis factor monitoring","volume":"9","year":"2013","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"(7 Suppl 4)","key":"R96-20250519","first-page":"1","article-title":"A special meeting review edition: Highlights in anti-tumor necrosis factor monitoring and antibody monitoring from the 2014 DDW meeting","volume":"10","year":"2014","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"R97-20250519","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2021.12.282","article-title":"Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease:Systematic review","volume":"162","author":"Kuenzig","year":"2022","journal-title":"Gastroenterology"},{"key":"R98-20250519","doi-asserted-by":"crossref","first-page":"207","DOI":"10.14740\/gr649w","article-title":"Clinical and sociodemographic aspects of inflammatory bowel disease patients","volume":"8","author":"Delmondes","year":"2015","journal-title":"Gastroenterology Res"},{"key":"R99-20250519","doi-asserted-by":"crossref","first-page":"e035538","DOI":"10.1136\/bmjopen-2019-035538","article-title":"International prospective observational study investigating the disease course and heterogeneity of paediatric-onset inflammatory bowel disease:The protocol of the PIBD-SETQuality inception cohort study","volume":"10","author":"Aardoom","year":"2020","journal-title":"BMJ Open"},{"key":"R100-20250519","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4103\/1319-3767.178524","article-title":"Impact of pediatric inflammatory bowel disease on linear growth:Data from a national cohort study in Saudi Arabia","volume":"22","author":"El Mouzan","year":"2016","journal-title":"Saudi J Gastroenterol"},{"key":"R101-20250519","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.3748\/wjg.v13.i15.2145","article-title":"Recent advances in basic and clinical aspects of inflammatory bowel disease:Which steps in the mucosal inflammation should we block for the treatment of inflammatory bowel disease?","volume":"13","author":"Asakura","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R102-20250519","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinf.2018.10.005","article-title":"Gut dysbiosis and paediatric Crohn's disease","volume":"78","author":"Brusaferro","year":"2019","journal-title":"J Infect"},{"key":"R103-20250519","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.3748\/wjg.v22.i5.1854","article-title":"Nutritional status of children with inflammatory bowel disease in Saudi Arabia","volume":"22","author":"El Mouzan","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R104-20250519","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2214.2010.01200.x","article-title":"Paediatric parenting stress in inflammatory bowel disease:Application of the pediatric inventory for parents","volume":"38","author":"Guilfoyle","year":"2012","journal-title":"Child Care Health Dev"},{"key":"R105-20250519","doi-asserted-by":"crossref","first-page":"201","DOI":"10.11622\/smedj.2013073","article-title":"Paediatric inflammatory bowel disease in a multiracial Asian country","volume":"54","author":"Chu","year":"2013","journal-title":"Singapore Med J"},{"key":"R106-20250519","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/apt.12928","article-title":"Predictors of response to infliximab in paediatric perianal Crohn's disease","volume":"40","author":"Dupont-Lucas","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R107-20250519","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0344-0338(11)80467-X","article-title":"Histology of the lower intestinal tract in Crohn's disease of children and adolescents. Multicentric Paediatric Crohn's Disease Study","volume":"186","author":"Schmitz-Moormann","year":"1990","journal-title":"Pathol Res Pract"},{"key":"R108-20250519","first-page":"208","article-title":"Paediatric gastric and intestinal Crohn's disease detected by (18)F-FDG PET\/CT","volume":"17","author":"Wang","year":"2014","journal-title":"Hell J Nucl Med"},{"key":"R109-20250519","doi-asserted-by":"crossref","first-page":"e034892","DOI":"10.1136\/bmjopen-2019-034892","article-title":"Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn's disease:Methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course","volume":"10","author":"Harris","year":"2020","journal-title":"BMJ Open"},{"key":"R110-20250519","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12969-017-0220-y","article-title":"Homocysteine, folate, hs-C-reactive protein, tumor necrosis factor alpha and inflammatory proteins: Are these biomarkers related to nutritional status and cardiovascular risk in childhood-onset systemic lupus erythematosus?","volume":"16","author":"Salom\u00e3o","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"R111-20250519","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12519-021-00486-1","article-title":"Risk factors for Clostridioides difficile infection in children and adolescents with inflammatory bowel disease: A systematic review and meta-analysis","volume":"18","author":"Fang","year":"2022","journal-title":"World J Pediatr"},{"key":"R112-20250519","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1097\/MIB.0000000000000219","article-title":"Clostridium difficile and pediatric inflammatory bowel disease:A prospective, comparative, multicenter, ESPGHAN study","volume":"20","author":"Martinelli","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"R113-20250519","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/flgastro-2017-100936","article-title":"Faecal microbiota transplantation as a treatment for inflammatory bowel disease:A national survey of adult and paediatric gastroenterologists in the UK","volume":"9","author":"Mcilroy","year":"2018","journal-title":"Frontline Gastroenterol"},{"key":"R114-20250519","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/ibd\/izac175","article-title":"Patient-reported outcomes correlate with microbial community composition independent of mucosal inflammation in pediatric inflammatory bowel disease","volume":"29","author":"Hellmann","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"R115-20250519","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/00365521.2016.1259653","article-title":"Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy","volume":"52","author":"Olbj\u00f8rn","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"R116-20250519","doi-asserted-by":"crossref","first-page":"799","DOI":"10.33549\/physiolres.934665","article-title":"The assessment of plasma fatty acid profiles in newly diagnosed treatment-naive paediatric Crohn's disease","volume":"70","author":"Schwarz","year":"2021","journal-title":"Physiol Res"},{"key":"R117-20250519","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1053\/j.gastro.2018.12.002","article-title":"Treatment of active crohn's disease with an ordinary food-based diet that replicates exclusive enteral nutrition","volume":"156","author":"Svolos","year":"2019","journal-title":"Gastroenterology"},{"key":"R118-20250519","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/ibd\/izad064","article-title":"Dual biologic or small molecule therapy in refractory pediatric inflammatory bowel disease (DOUBLE-PIBD):A multicenter study from the pediatric IBD Porto Group of ESPGHAN","volume":"30","author":"Yerushalmy-Feler","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"R119-20250519","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00330-010-1976-3","article-title":"MR enterography versus capsule endoscopy in paediatric patients with suspected Crohn's disease","volume":"21","author":"Casciani","year":"2011","journal-title":"Eur Radiol"},{"key":"R120-20250519","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/MPG.0b013e318231d984","article-title":"Diagnostic workup of paediatric patients with inflammatory bowel disease in Europe: Results of a 5-year audit of the EUROKIDS registry","volume":"54","author":"De Bie","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R121-20250519","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.crohns.2011.07.008","article-title":"Diagnostic yield of upper endoscopy in paediatric patients with Crohn's disease and ulcerative colitis. Subanalysis of the HUPIR registry","volume":"6","author":"Kovacs","year":"2012","journal-title":"J Crohns Colitis"},{"key":"R122-20250519","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/MPG.0000000000002178","article-title":"Quantitative analysis of apparent diffusion coefficient for disease assessment in paediatric inflammatory bowel disease","volume":"68","author":"Scionti","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R123-20250519","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.3748\/wjg.v24.i35.4014","article-title":"Endoscopy in inflammatory bowel disease:Role in diagnosis, management, and treatment","volume":"24","author":"Spiceland","year":"2018","journal-title":"World J Gastroenterol"},{"key":"R124-20250519","first-page":"213","article-title":"Clinical usefulness of the Mucosal Inflammation Noninvasive Index in newly diagnosed paediatric Crohn's disease patients","volume":"17","author":"Herman","year":"2022","journal-title":"Prz Gastroenterol"},{"key":"R125-20250519","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/apt.12323","article-title":"Systematic review: MRI enterography for assessment of small bowel involvement in paediatric Crohn's disease","volume":"37","author":"Giles","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R126-20250519","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/pgmj.2010.106641","article-title":"The smaller bowel:Imaging the small bowel in paediatric Crohn's disease","volume":"87","author":"Stuart","year":"2011","journal-title":"Postgrad Med J"},{"key":"R127-20250519","first-page":"230","article-title":"Serological markers in inflammatory bowel disease:A review of their clinical utility","volume":"74","author":"Barahona-Garrido","year":"2009","journal-title":"Rev Gastroenterol Mex"},{"key":"R128-20250519","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejrad.2018.02.029","article-title":"Paediatric magnetic resonance enterography in inflammatory bowel disease","volume":"102","author":"Greer","year":"2018","journal-title":"Eur J Radiol"},{"key":"R129-20250519","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s00535-013-0815-0","article-title":"Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn's disease","volume":"49","author":"Grover","year":"2014","journal-title":"J Gastroenterol"},{"key":"R130-20250519","first-page":"190","article-title":"A review of magnetic resonance enterography based Crohn's disease activity indices in paediatric patients","volume":"17","author":"Herman","year":"2022","journal-title":"Prz Gastroenterol"},{"key":"R131-20250519","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/ecco-jcc\/jjab111","article-title":"Diagnostic performance of diffusion-weighted imaging for evaluation of bowel inflammation in paediatric inflammatory bowel disease:A systematic review and meta-analysis","volume":"16","author":"Kim","year":"2022","journal-title":"J Crohns Colitis"},{"key":"R132-20250519","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1007\/s00330-012-2482-6","article-title":"Differences in the location and activity of intestinal Crohn's disease lesions between adult and paediatric patients detected with MRI","volume":"22","author":"Maccioni","year":"2012","journal-title":"Eur Radiol"},{"key":"R133-20250519","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.crad.2013.04.014","article-title":"Contrast-enhanced MR enterography as a stand-alone tool to evaluate Crohn's disease in a paediatric population","volume":"68","author":"Spieler","year":"2013","journal-title":"Clin Radiol"},{"key":"R134-20250519","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.ultrasmedbio.2017.04.028","article-title":"Small bowel ultrasound beyond inflammatory bowel disease:An updated review of the recent literature","volume":"43","author":"Cavalcoli","year":"2017","journal-title":"Ultrasound Med Biol"},{"key":"R135-20250519","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0009-9260(79)80033-1","article-title":"Bowel wall thickness as a differentiating feature between ulcerative colitis and Crohn's disease of the colon","volume":"30","author":"Bartram","year":"1979","journal-title":"Clin Radiol"},{"key":"R136-20250519","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1572-0241.2001.03546.x","article-title":"Magnetic resonance spectroscopy:A new test for differentiating ulcerative colitis from Crohn's disease?","volume":"96","author":"Mandal","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R137-20250519","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00431-002-1152-0","article-title":"Ultrasound in the diagnosis of Crohn disease in childhood","volume":"162","author":"Caiulo","year":"2003","journal-title":"Eur J Pediatr"},{"key":"R138-20250519","doi-asserted-by":"crossref","first-page":"129","DOI":"10.14309\/ajg.0000000000002016","article-title":"Humoral immune response and safety of SARS-CoV-2 vaccination in pediatric inflammatory bowel disease","volume":"118","author":"Kastl","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"R139-20250519","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00247-019-04375-8","article-title":"European Society of paediatric radiology abdominal imaging task force:Statement on imaging in very early onset inflammatory bowel disease","volume":"49","author":"Watson","year":"2019","journal-title":"Pediatr Radiol"},{"key":"R140-20250519","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/ecco-jcc\/jjx125","article-title":"The long-term predictive properties of the Paris classification in paediatric inflammatory bowel disease patients","volume":"12","author":"Assa","year":"2018","journal-title":"J Crohns Colitis"},{"key":"R141-20250519","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/00365521.2019.1710765","article-title":"From Paris to Montreal:Disease regression is common during long term follow-up of paediatric Crohn's disease","volume":"55","author":"Davies","year":"2020","journal-title":"Scand J Gastroenterol"},{"key":"R142-20250519","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jclinepi.2008.09.008","article-title":"Mathematical weighting of a clinimetric index (Pediatric Ulcerative Colitis Activity Index) was superior to the judgmental approach","volume":"62","author":"Turner","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"R143-20250519","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.anpedi.2011.03.011","article-title":"Aplicaci\u00f3n de los criterios de Oporto para el diagn\u00f3stico de enfermedad inflamatoria intestinal pedi\u00e1trica en un centro pedi\u00e1trico de referencia","volume":"75","author":"Mart\u00edn","year":"2011","journal-title":"An Pediatr (Engl Ed)"},{"key":"R144-20250519","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1053\/j.gastro.2008.06.081","article-title":"Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease","volume":"135","author":"Van Limbergen","year":"2008","journal-title":"Gastroenterology"},{"key":"R145-20250519","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-222015","article-title":"Cryptosporidium diagnosed on endoscopic biopsy in a paediatric patient with inflammatory bowel disease","author":"Cheung","year":"2018","journal-title":"BMJ Case Rep"},{"key":"R146-20250519","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/JIR.S65979","article-title":"Inflammatory bowel disease:Clinical aspects and treatments","volume":"7","author":"Fakhoury","year":"2014","journal-title":"J Inflamm Res"},{"key":"R147-20250519","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1651-2227.1994.tb13224.x","article-title":"A paediatric Crohn's disease activity index (PCDAI). Is it useful?","volume":"83","author":"Harms","year":"1994","journal-title":"Acta Paediatr"},{"key":"R148-20250519","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/ecco-jcc\/jjad126","article-title":"Faecal bacteriome and metabolome profiles associated with decreased mucosal inflammatory activity upon anti-TNF therapy in paediatric Crohn's disease","volume":"18","author":"Hurych","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R149-20250519","first-page":"380","article-title":"Serological markers in inflammatory bowel disease:A review of their clinical utility","volume":"74","author":"Barahona-Garrido","year":"2009","journal-title":"Rev Gastroenterol Mex"},{"key":"R150-20250519","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1365-2036.2011.04805.x","article-title":"Faecal chitinase 3-like-1:A novel biomarker of disease activity in paediatric inflammatory bowel disease","volume":"34","author":"Aomatsu","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R151-20250519","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1097\/MPG.0000000000001847","article-title":"Faecal calprotectin","volume":"66","author":"Ashton","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R152-20250519","first-page":"519","article-title":"Incidence and phenotype at diagnosis of very-early-onset compared with later-onset paediatric inflammatory bowel disease: A population-based study [1988\u20132011]","volume":"11","author":"Bequet","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R153-20250519","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1097\/MPG.0000000000000737","article-title":"Clostridium difficile Ileitis in pediatric inflammatory bowel disease","volume":"64","author":"Butler","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R154-20250519","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cgh.2016.11.028","article-title":"Fecal microbiota transplantation for recurrent clostridium difficile infection in patients with inflammatory bowel disease:A single-center experience","volume":"15","author":"Chin","year":"2017","journal-title":"Clinical Gastroenterol Hepatol"},{"key":"R155-20250519","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/apt.13326","article-title":"Microbiome changes associated with sustained eradication of Clostridium difficile after single faecal microbiota transplantation in children with and without inflammatory bowel disease","volume":"42","author":"Hourigan","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R156-20250519","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1097\/MIB.0000000000000666","article-title":"Clostridium difficile infection in pediatric inflammatory bowel disease","volume":"22","author":"Hourigan","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"R157-20250519","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/MIB.0000000000000309","article-title":"Testing for clostridium difficile in patients newly diagnosed with inflammatory bowel disease in a community setting","volume":"21","author":"Krishnarao","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"R158-20250519","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.dld.2012.07.020","article-title":"Enteroscopy in paediatric Crohn's disease","volume":"45","author":"Di Nardo","year":"2013","journal-title":"Dig Liver Dis"},{"key":"R159-20250519","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.dld.2010.10.004","article-title":"Usefulness of wireless capsule endoscopy in paediatric inflammatory bowel disease","volume":"43","author":"Di","year":"2011","journal-title":"Dig Liver Dis"},{"key":"R160-20250519","doi-asserted-by":"crossref","first-page":"793","DOI":"10.12669\/pjms.334.12926","article-title":"Paediatric inflammatory bowel disease:Clinical presentation and disease location","volume":"33","author":"Abdul Aziz","year":"2017","journal-title":"Pak J Med Sci"},{"key":"R161-20250519","first-page":"258","article-title":"The Diagnostic Utility of Lip Biopsy in Paediatric Crohn's Disease: A 10-year Single-centre Retrospective Study","volume":"59","author":"Neville","year":"2024","journal-title":"J Pediatr Surg"},{"key":"R162-20250519","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.crad.2017.02.008","article-title":"There is good agreement between MR enterography and bowel ultrasound with regards to disease location and activity in paediatric inflammatory bowel disease","volume":"72","author":"Barber","year":"2017","journal-title":"Clin Radiol"},{"key":"R163-20250519","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1136\/archdischild-2014-306043","article-title":"Indications for gastrointestinal endoscopy in childhood","volume":"101","author":"Belsha","year":"2016","journal-title":"Arch Dis Child"},{"key":"R164-20250519","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.21037\/tp-23-210","article-title":"Recent developments in the assessment and management of inflammatory bowel disease in childhood: A narrative review","volume":"12","author":"Green","year":"2023","journal-title":"Transl Pediatr"},{"key":"R165-20250519","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.3390\/diagnostics13122032","article-title":"Is panenteric Pillcam\u2122 Crohn's capsule endoscopy ready for widespread use? A narrative review","volume":"13","author":"Toskas","year":"2023","journal-title":"Diagnostics"},{"key":"R166-20250519","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.gie.2018.07.035","article-title":"Utility of video capsule endoscopy for longitudinal monitoring of Crohn's disease activity in the small bowel:A prospective study","volume":"88","author":"Melmed","year":"2018","journal-title":"Gastrointest Endosc"},{"key":"R167-20250519","doi-asserted-by":"crossref","first-page":"532","DOI":"10.5946\/ce.2021.224","article-title":"Capsule enteroscopy versus small-bowel ultrasonography for the detection and differential diagnosis of intestinal diseases","volume":"55","author":"Elli","year":"2022","journal-title":"Clin Endosc"},{"key":"R168-20250519","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/ecco-jcc\/jjab175","article-title":"Point-of-care intestinal ultrasound in IBD patients:Disease management and diagnostic yield in a real-world cohort and proposal of a point-of-care algorithm","volume":"16","author":"Bots","year":"2022","journal-title":"J Crohns Colitis"},{"key":"R169-20250519","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/gastro\/goaa088","article-title":"Impact of intestinal ultrasound with a portable system in the management of Crohn's disease","volume":"9","author":"Gonen","year":"2021","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"R170-20250519","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1097\/MPG.0000000000003442","article-title":"A healthcare physician can be trained to perform intestinal ultrasound in children with inflammatory bowel disease","volume":"74","author":"van Wassenaer","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R171-20250519","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00042737-200503000-00005","article-title":"Imaging inflammatory bowel disease using bowel ultrasound","volume":"17","author":"Parente","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R172-20250519","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/archdischild-2011-300633","article-title":"Association of paediatric inflammatory bowel disease with other immune-mediated diseases","volume":"96","author":"Kappelman","year":"2011","journal-title":"Arch Dis Child"},{"key":"R173-20250519","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1080\/00365521.2021.1947368","article-title":"The pediatric ulcerative colitis activity index (PUCAI) predicts steroid-failure in adults with acute severe colitis","volume":"56","author":"Atia","year":"2021","journal-title":"Scand J Gastroenterol"},{"key":"R174-20250519","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/ibd.20867","article-title":"Appraisal of the pediatric ulcerative colitis activity index (PUCAI)","volume":"15","author":"Turner","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"R175-20250519","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ibd.21649","article-title":"Mathematical weighting of the pediatric Crohn\u02bcs disease activity index (PCDAI) and comparison with its other short versions","volume":"18","author":"Turner","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R176-20250519","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.gastro.2007.05.029","article-title":"Development, validation, and evaluation of a pediatric ulcerative colitis activity index:A prospective multicenter study","volume":"133","author":"Turner","year":"2007","journal-title":"Gastroenterology"},{"key":"R177-20250519","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/MPG.0000000000003853","article-title":"Comparison of clinical outcomes in pediatric patients with ileocolonic crohn disease treated with infliximab versus adalimumab","volume":"77","author":"Fanous","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R178-20250519","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1007\/s11136-023-03409-x","article-title":"A comparison of the child health utility 9D and the health utilities index for estimating health utilities in pediatric inflammatory bowel disease","volume":"32","author":"Bashir","year":"2023","journal-title":"Qual Life Res"},{"key":"R179-20250519","doi-asserted-by":"crossref","first-page":"otad037","DOI":"10.1093\/crocol\/otad037","article-title":"Use of standardized inflammatory bowel disease endoscopy scores in clinical practice","volume":"5","author":"Gaidos","year":"2023","journal-title":"Crohns Colitis 360"},{"key":"R180-20250519","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/ecco-jcc\/jjw104","article-title":"The Ulcerative colitis endoscopic index of severity is useful to predict medium- to long-term prognosis in ulcerative colitis patients with clinical remission","volume":"10","author":"Arai","year":"2016","journal-title":"J Crohns Colitis"},{"key":"R181-20250519","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.3748\/wjg.v23.i18.3322","article-title":"Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis","volume":"23","author":"Kerur","year":"2017","journal-title":"World J Gastroenterol"},{"key":"R182-20250519","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.dld.2017.04.021","article-title":"Fecal calprotectin as an alternative to ulcerative colitis endoscopic index of severity to predict the response to corticosteroids of acute severe ulcerative colitis:A prospective observational study","volume":"49","author":"Xie","year":"2017","journal-title":"Dig Liver Dis"},{"key":"R183-20250519","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/ibd\/izad074","article-title":"Predicting endoscopic improvement in ulcerative colitis using the ulcerative colitis severity index","volume":"30","author":"Wong","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"R184-20250519","doi-asserted-by":"crossref","first-page":"e35799","DOI":"10.1097\/MD.0000000000035799","article-title":"The ulcerative colitis endoscopic index of severity score is superior to reflecting long-term prognosis in ulcerative colitis patients treated with vedolizumab","volume":"102","author":"Yan","year":"2023","journal-title":"Medicine"},{"key":"R185-20250519","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/MPG.0000000000003018","article-title":"Moderate-to-severe endoscopic inflammation is frequent after clinical remission in pediatric ulcerative colitis","volume":"72","author":"Sarbagili-Shabat","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R186-20250519","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5223\/pghn.2018.21.1.1","article-title":"Early biologic treatment in pediatric Crohn's disease:Catching the therapeutic window of opportunity in early disease by treat-to-target","volume":"21","author":"Kang","year":"2018","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"R187-20250519","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.cgh.2018.10.015","article-title":"A treat to target strategy using panenteric capsule endoscopy in pediatric patients with Crohn's disease","volume":"17","author":"Oliva","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R188-20250519","doi-asserted-by":"crossref","first-page":"501","DOI":"10.12998\/wjcc.v6.i12.501","article-title":"Treat-to-target in Crohn's disease: Will transmural healing become a therapeutic endpoint?","volume":"6","author":"Serban","year":"2018","journal-title":"World J Clin Cases"},{"key":"R189-20250519","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/MPG.0000000000002458","article-title":"Time-to-reach target calprotectin level in newly diagnosed patients with inflammatory bowel disease","volume":"69","author":"Haisma","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R190-20250519","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40272-013-0046-0","article-title":"Endocrine therapy for growth retardation in paediatric inflammatory bowel disease","volume":"16","author":"Altowati","year":"2014","journal-title":"Pediatric Drugs"},{"key":"R191-20250519","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/apa.15383","article-title":"Growth failure is rare in a contemporary cohort of paediatric inflammatory bowel disease patients","volume":"110","author":"Ashton","year":"2021","journal-title":"Acta Paediatr"},{"key":"R192-20250519","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1016\/j.clnu.2020.04.012","article-title":"Partial enteral nutrition has no benefit on bone health but improves growth in paediatric patients with quiescent or mild Crohn's disease","volume":"39","author":"Br\u00fcckner","year":"2020","journal-title":"Clinical Nutrition"},{"issue":"(Suppl. 1)","key":"R193-20250519","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000064759","article-title":"Growth in paediatric Crohn's disease","volume":"58","author":"Cezard","year":"2002","journal-title":"Horm Res Paediatr"},{"key":"R194-20250519","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/MCO.0000000000000402","article-title":"Exclusive enteral nutrition for inducing remission in inflammatory bowel disease in paediatric patients","volume":"20","author":"Assa","year":"2017","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"R195-20250519","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/apt.12230","article-title":"Clinical progress in the two years following a course of exclusive enteral nutrition in 109 paediatric patients with Crohn's disease","volume":"37","author":"Cameron","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R196-20250519","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ecco-jcc\/jjx060","article-title":"Exclusive enteral nutrition therapy in paediatric Crohn's disease results in long-term avoidance of corticosteroids: Results of a propensity-score matched cohort analysis","volume":"11","author":"Connors","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R197-20250519","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cgh.2019.04.012","article-title":"Development and validation of the mucosal inflammation noninvasive index for pediatric Crohn's disease","volume":"18","author":"Cozijnsen","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R198-20250519","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.3748\/wjg.v27.i30.5100","article-title":"Assessing disease activity using the pediatric Crohn's disease activity index:Can we use subjective or objective parameters alone?","volume":"27","author":"Grant","year":"2021","journal-title":"World J Gastroenterol"},{"key":"R199-20250519","doi-asserted-by":"crossref","first-page":"44","DOI":"10.5114\/pg.2016.64746","article-title":"Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn's disease","volume":"1","author":"Szymanska","year":"2017","journal-title":"Gastroenterol Rev"},{"key":"R200-20250519","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II:An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"R201-20250519","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/ecco-jcc\/jjac005","article-title":"existing prediction models of disease course in paediatric crohn's disease are poorly replicated in a prospective inception cohort","volume":"16","author":"Atia","year":"2022","journal-title":"J Crohns Colitis"},{"key":"R202-20250519","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/apt.15016","article-title":"Response to treatment is more important than disease severity at diagnosis for prediction of early relapse in new-onset paediatric Crohn's disease","volume":"48","author":"Ziv-Baran","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"R203-20250519","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/ecco-jcc\/jjx150","article-title":"Differences in outcomes over time with exclusive enteral nutrition compared with steroids in children with mild to moderate Crohn's disease:Results from the growth CD study","volume":"12","author":"Cohen-Dolev","year":"2018","journal-title":"J Crohns Colitis"},{"key":"R204-20250519","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.3390\/jcm11144157","article-title":"Predictors of anti-TNF therapy failure among Inflammatory Bowel Disease (IBD) patients in Saudi Arabia: A single-center study","volume":"11","author":"Alharbi","year":"2022","journal-title":"J Clin Med"},{"key":"R205-20250519","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/apt.17109","article-title":"Meta-analysis:Efficacy of exclusive enteral nutrition as induction therapy on disease activity index, inflammation and growth factors in paediatric Crohn's disease","volume":"56","author":"Sohouli","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"R206-20250519","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1007\/s00431-022-04496-7","article-title":"Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn's disease","volume":"181","author":"Jongsma","year":"2022","journal-title":"Eur J Pediatr"},{"key":"R207-20250519","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clnesp.2022.04.006","article-title":"Exclusive enteral nutrition practices in the management of Crohn's disease:A cross sectional survey of specialist paediatric dietitians","volume":"49","author":"Jackman","year":"2022","journal-title":"Clin Nutr ESPEN"},{"key":"R208-20250519","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/apt.17135","article-title":"Editorial:Further support for exclusive enteral nutrition in paediatric Crohn's disease","volume":"56","author":"Hudson","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"R209-20250519","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/apt.12770","article-title":"Repeated exclusive enteral nutrition in the treatment of paediatric Crohn's disease:Predictors of efficacy and outcome","volume":"39","author":"Frivolt","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R210-20250519","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/MEG.0000000000000027","article-title":"Standard versus rapid food reintroduction after exclusive enteral nutritional therapy in paediatric Crohn's disease","volume":"26","author":"Faiman","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R211-20250519","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/423817","article-title":"Paediatric inflammatory bowel disease:A mechanistic approach to investigate exclusive enteral nutrition treatment","volume":"2014","author":"Nahidi","year":"2014","journal-title":"Scientifica (Cairo)"},{"key":"R212-20250519","doi-asserted-by":"crossref","first-page":"108992","DOI":"10.1016\/j.jnutbio.2022.108992","article-title":"Comparison of antagonistic effects of nanoparticle-selenium, selenium-enriched yeast and sodium selenite against cadmium-induced cardiotoxicity via AHR\/CAR\/PXR\/Nrf2 pathways activation","volume":"105","author":"Ge","year":"2022","journal-title":"J Nutr Biochem"},{"key":"R213-20250519","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3390\/nu13010212","article-title":"Nutritional therapy strategies in pediatric Crohn's disease","volume":"13","author":"Verburgt","year":"2021","journal-title":"Nutrients"},{"key":"R214-20250519","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1053\/j.gastro.2019.04.021","article-title":"Crohn's disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial","volume":"157","author":"Levine","year":"2019","journal-title":"Gastroenterology"},{"key":"R215-20250519","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejpb.2016.03.018","article-title":"Development of a zero-order sustained-release tablet containing mesalazine and budesonide intended to treat the distal gastrointestinal tract in inflammatory bowel disease","volume":"103","author":"Gareb","year":"2016","journal-title":"Eur J Pharm Biopharm"},{"key":"R216-20250519","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1515\/pjvs-2016-0020","article-title":"Clinical, endoscopic and histopathological evaluation of the efficacy of budesonide in the treatment of inflammatory bowel disease in dogs","volume":"19","author":"Rychlik","year":"2016","journal-title":"Pol J Vet Sci"},{"key":"R217-20250519","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1080\/03639045.2018.1434194","article-title":"Process, optimization, and characterization of budesonide-loaded nanostructured lipid carriers for the treatment of inflammatory bowel disease","volume":"44","author":"Sinhmar","year":"2018","journal-title":"Drug Dev Ind Pharm"},{"key":"R218-20250519","first-page":"743","article-title":"The effect of budesonide on the expression of Ki-67 and PCNA and the apoptotic index in dogs with inflammatory bowel disease","volume":"20","author":"Szweda","year":"2017","journal-title":"Pol J Vet Sci"},{"key":"R219-20250519","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/0300-2977(95)00090-9","article-title":"Budesonide in inflammatory bowel disease","volume":"48","author":"Lamers","year":"1996","journal-title":"Neth J Med"},{"key":"R220-20250519","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.dld.2005.10.005","article-title":"Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease","volume":"38","author":"Berni","year":"2006","journal-title":"Dig Liver Dis"},{"key":"R221-20250519","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12519-018-0204-0","article-title":"Exclusive enteral nutrition versus corticosteroids for treatment of pediatric Crohn's disease:A meta-analysis","volume":"15","author":"Yu","year":"2019","journal-title":"World J Pediatr"},{"key":"R222-20250519","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1590\/S1516-31802003000300006","article-title":"Treatment of refractory juvenile idiopathic arthritis via pulse therapy using methylprednisolone and cyclophosphamide","volume":"121","author":"Castro","year":"2003","journal-title":"Sao Paulo Med J"},{"key":"R223-20250519","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s002280050512","article-title":"Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission","volume":"54","author":"Faure","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"R224-20250519","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13256-015-0545-4","article-title":"High-dose methylprednisolone pulse therapy for treatment of refractory intestinal involvement caused by Henoch\u2013Sch\u00f6nlein purpura:A case report","volume":"9","author":"Kang","year":"2015","journal-title":"J Med Case Rep"},{"key":"R225-20250519","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0887-8994(98)00065-4","article-title":"Rapid recovery from transverse myelopathy in children treated with methylprednisolone","volume":"19","author":"Lahat","year":"1998","journal-title":"Pediatr Neurol"},{"key":"R226-20250519","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/03007995.2017.1313213","article-title":"Enteric-coated budesonide for the induction and maintenance of remission of Crohn's disease in children","volume":"33","author":"Cohen","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"R227-20250519","doi-asserted-by":"crossref","first-page":"120422","DOI":"10.1016\/j.carbpol.2022.120422","article-title":"Colonic budesonide delivery by multistimuli alginate\/Eudragit\u00aeFS 30D\/inulin-based microspheres as a paediatric formulation","volume":"302","author":"D'Amico","year":"2023","journal-title":"Carbohydr Polym"},{"key":"R228-20250519","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/jcag\/gwy018","article-title":"Budesonide for the induction and maintenance of Remission in Crohn's disease:Systematic review and meta-analysis for the Cochrane collaboration","volume":"1","author":"Kuenzig","year":"2018","journal-title":"J Can Assoc Gastroenterol"},{"key":"R229-20250519","doi-asserted-by":"crossref","first-page":"115489","DOI":"10.1016\/j.biopha.2023.115489","article-title":"Budesonide, an anti-inflammatory drug, exacerbate clostridioides difficile colitis in mice","volume":"167","author":"Lin","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"R230-20250519","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/MPG.0b013e31824a09c2","article-title":"Budesonide use in pediatric Crohn disease","volume":"55","author":"Otley","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R231-20250519","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1586\/eci.11.34","article-title":"Budesonide in the treatment of inflammatory bowel disease","volume":"7","author":"Silverman","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"key":"R232-20250519","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.crohns.2007.07.001","article-title":"Infliximab in paediatric inflammatory bowel disease","volume":"1","author":"Vilar","year":"2007","journal-title":"J Crohns Colitis"},{"key":"R233-20250519","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1365-2036.2011.04603.x","article-title":"A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease","volume":"33","author":"Russell","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R234-20250519","doi-asserted-by":"crossref","first-page":"565","DOI":"10.14309\/ajg.0000000000002552","article-title":"Adalimumab vs infliximab in luminal pediatric Crohn's disease: Comparable outcomes in a prospective multicenter cohort study","volume":"119","author":"deBruyn","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"R235-20250519","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/MIB.0000000000001072","article-title":"Treatment persistence for infliximab versus adalimumab in Crohn\u02bcs disease","volume":"23","author":"Olivera","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"R236-20250519","doi-asserted-by":"crossref","first-page":"e000123","DOI":"10.1136\/bmjgast-2016-000123","article-title":"Top-down infliximab study in kids with Crohn's disease (TISKids):An international multicentre randomised controlled trial","volume":"3","author":"Cozijnsen","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"key":"R237-20250519","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2036.2010.04507.x","article-title":"The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited","volume":"33","author":"De Bie","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R238-20250519","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/MPG.0000000000002631","article-title":"Pharmacokinetics, pharmacodynamics, and immunogenicity of infliximab in pediatric inflammatory bowel disease","volume":"70","author":"Winter","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R239-20250519","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/ibd.20534","article-title":"Short-term response to adalimumab in childhood inflammatory bowel disease","volume":"14","author":"Noe","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"R244-20250519","first-page":"555","article-title":"Sulfasalazine and new analogues in inflammatory bowel disease, with focus on Crohn's disease","volume":"50","author":"van Hees","year":"1987","journal-title":"Acta Gastroenterol Belg"},{"key":"R245-20250519","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.4049\/jimmunol.156.5.1937","article-title":"The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites","volume":"156","author":"Gadangi","year":"1996","journal-title":"J Immunol"},{"key":"R246-20250519","first-page":"CD008870","article-title":"Aminosalicylates for induction of remission or response in Crohn's disease","volume":"2016","author":"Lim","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R247-20250519","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.dld.2005.08.003","article-title":"TPMT genotype and the use of thiopurines in paediatric inflammatory bowel disease","volume":"37","author":"Stocco","year":"2005","journal-title":"Dig Liver Dis"},{"key":"R248-20250519","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/MPG.0000000000002566","article-title":"Role of thiopurines in pediatric inflammatory bowel diseases","volume":"70","author":"Atia","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R249-20250519","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10620-021-06836-3","article-title":"Adverse events of thiopurine therapy in pediatric inflammatory bowel disease and correlations with metabolites:A cohort study","volume":"67","author":"Jagt","year":"2022","journal-title":"Dig Dis Sci"},{"key":"R250-20250519","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/apt.13361","article-title":"Impact of early thiopurines on surgery in 2770 children and young people diagnosed with inflammatory bowel disease:A national population-based study","volume":"42","author":"Chhaya","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R251-20250519","doi-asserted-by":"crossref","first-page":"e1513","DOI":"10.1097\/MD.0000000000001513","article-title":"Safety profile of thiopurines in Crohn disease","volume":"94","author":"Qiu","year":"2015","journal-title":"Medicine"},{"key":"R252-20250519","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4292\/wjgpt.v5.i2.63","article-title":"Use of thiopurines in inflammatory bowel disease:Safety issues","volume":"5","author":"Konidari","year":"2014","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"R253-20250519","first-page":"izad195","article-title":"Management of perianal fistulizing Crohn's Disease","author":"Singh","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"R254-20250519","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s12664-024-01524-2","article-title":"Perianal fistulizing Crohn's disease:Current perspectives on diagnosis, monitoring and management with a focus on emerging therapies","volume":"43","author":"Devi","year":"2024","journal-title":"Indian J Gastroenterol"},{"key":"R255-20250519","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/MEG.0000000000001575","article-title":"Is MRI healing the target in treating perianal fistulizing Crohn's disease?","volume":"32","author":"Eman","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R256-20250519","doi-asserted-by":"crossref","first-page":"e20152878","DOI":"10.1542\/peds.2015-2878","article-title":"Fistulizing Crohn's Disease Presenting After Surgery on a Perianal Lesion","volume":"137","author":"Singer","year":"2016","journal-title":"Pediatrics"},{"key":"R257-20250519","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.3748\/wjg.v21.i8.2475","article-title":"Long-term outcome of infliximab combined with surgery for perianal fistulizing Crohn's disease","volume":"21","author":"Yang","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R258-20250519","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1007\/s10620-008-0545-y","article-title":"Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn's disease","volume":"54","author":"Tougeron","year":"2009","journal-title":"Dig Dis Sci"},{"key":"R259-20250519","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10151-021-02460-5","article-title":"Surgical strategy for supralevator abscess in Perianal Crohn's disease:Emergency surgery and residual complex fistula","volume":"25","author":"Jeri-McFarlane","year":"2021","journal-title":"Tech Coloproctol"},{"key":"R260-20250519","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/17474124.2016.1185363","article-title":"Methotrexate in Crohn's disease:A new face for an old drug?","volume":"10","author":"Cesarini","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R261-20250519","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1093\/ibd\/izy078","article-title":"Methotrexate for the treatment of pediatric Crohn's disease:A systematic review and meta-analysis","volume":"24","author":"Colman","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"R262-20250519","doi-asserted-by":"crossref","first-page":"211","DOI":"10.17305\/bjbms.2018.2792","article-title":"Therapeutic role of methotrexate in pediatric Crohn's disease","volume":"18","author":"Djuri\u0107","year":"2018","journal-title":"Bosn J Basic Med Sci"},{"key":"R263-20250519","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.3109\/00365521.2015.1031166","article-title":"Methotrexate is an efficient therapeutic alternative in children with thiopurine-resistant Crohn's disease","volume":"50","author":"Hojsak","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"R264-20250519","doi-asserted-by":"crossref","first-page":"175628482110430","DOI":"10.1177\/17562848211043017","article-title":"Short-term tolerability and effectiveness of methotrexate monotherapy in adult patients with Crohn's disease: A retrospective study","volume":"14","author":"Hong","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"R265-20250519","first-page":"868","article-title":"Successful methotrexate treatment of oesophageal pemphigus vulgaris in an immunosuppressed patient with Crohn's disease","volume":"95","author":"Horv\u00e1th","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"R266-20250519","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1111\/ijd.16417","article-title":"Methotrexate for recalcitrant cutaneous Crohn's disease:A dermatology-based case series with emphasis on outcomes","volume":"62","author":"Hrin","year":"2023","journal-title":"Int J Dermatol"},{"key":"R267-20250519","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/MIB.0000000000001022","article-title":"Methotrexate for refractory Crohn\u02bcs disease compared with thiopurines","volume":"23","author":"Huang","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"R268-20250519","first-page":"CD006884","article-title":"Methotrexate for maintenance of remission in Crohn's disease","volume":"2014","author":"Patel","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R269-20250519","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1136\/gutjnl-2014-307964","article-title":"Efficacy of oral methotrexate in paediatric Crohn's disease: A multicentre propensity score study","volume":"64","author":"Turner","year":"2015","journal-title":"Gut"},{"key":"R270-20250519","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2710.2009.01041.x","article-title":"Thiopurine S -methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients","volume":"35","author":"Gazouli","year":"2010","journal-title":"J Clin Pharm Ther"},{"key":"R271-20250519","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jmoldx.2022.06.007","article-title":"TPMT and NUDT15 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase","volume":"24","author":"Pratt","year":"2022","journal-title":"J Mol Diagn"},{"key":"R272-20250519","first-page":"CD00006","article-title":"Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease","volume":"2016","author":"Chande","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R273-20250519","first-page":"404","article-title":"Toxicity profile of thiopurines in inflammatory bowel disease:A retrospective cohort analysis","volume":"98","author":"Labidi","year":"2020","journal-title":"Tunis Med"},{"key":"R274-20250519","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1365-2036.2007.03278.x","article-title":"Thiopurine metabolite monitoring in paediatric inflammatory bowel disease","volume":"25","author":"Ooi","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R275-20250519","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/ecco-jcc\/jjac044","article-title":"Favourable tolerability and drug survival of tioguanine versus methotrexate after failure of conventional thiopurines in Crohn's disease","volume":"16","author":"Savelkoul","year":"2022","journal-title":"J Crohns Colitis"},{"key":"R276-20250519","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jama.2019.0709","article-title":"Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease","volume":"321","author":"Walker","year":"2019","journal-title":"JAMA"},{"key":"R277-20250519","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"R278-20250519","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.crohns.2013.04.006","article-title":"Extra-intestinal malignancies in inflammatory bowel disease:Results of the 3rd ECCO Pathogenesis Scientific Workshop (III)","volume":"8","author":"Magro","year":"2014","journal-title":"J Crohns Colitis"},{"key":"R279-20250519","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/MPG.0000000000003197","article-title":"Epstein-Barr virus status and subsequent thiopurine exposure within a paediatric inflammatory bowel disease population","volume":"73","author":"Harris","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R280-20250519","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/s41423-021-00694-9","article-title":"Reactivation of latent tuberculosis with TNF inhibitors:Critical role of the beta 2 chain of the IL-12 receptor","volume":"18","author":"Robert","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"R281-20250519","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/MOG.0000000000000546","article-title":"Positioning biologics and new therapies in the management of inflammatory bowel disease","volume":"35","author":"Honap","year":"2019","journal-title":"Curr Opin Gastroenterol"},{"key":"R282-20250519","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1093\/ibd\/izad088","article-title":"Prior authorization of biologics in the management of inflammatory bowel disease","volume":"29","author":"Loeb","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"R283-20250519","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3904\/kjim.2022.152","article-title":"Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors:Novel biologics and small-molecule drugs","volume":"37","author":"Na","year":"2022","journal-title":"Korean J Intern Med"},{"key":"R284-20250519","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/MOG.0000000000000729","article-title":"Molecular targets and the use of biologics in the management of small bowel fibrosis in inflammatory bowel disease","volume":"37","author":"Abdulla","year":"2021","journal-title":"Curr Opin Gastroenterol"},{"key":"R285-20250519","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/cld.1005","article-title":"The Impact of Biologics for the Management of Inflammatory Bowel Disease on Liver Enzymes","volume":"16","author":"Aby","year":"2020","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"R286-20250519","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/apt.16952","article-title":"Review article:Latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression\u2014risks, screening, diagnosis and management","volume":"56","author":"Fehily","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"R287-20250519","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3390\/jpm12030507","article-title":"Impact of immunosuppressive therapy on the performance of latent tuberculosis screening tests in patients with inflammatory bowel disease:A systematic review and meta-analysis","volume":"12","author":"Park","year":"2022","journal-title":"J Pers Med"},{"key":"R288-20250519","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1007\/s10620-018-5202-5","article-title":"Maintenance adalimumab concentrations are associated with biochemical, endoscopic, and histologic remission in inflammatory bowel disease","volume":"63","author":"Juncadella","year":"2018","journal-title":"Dig Dis Sci"},{"key":"R289-20250519","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5217\/ir.2014.12.4.287","article-title":"Safety and efficacy of adalimumab for patients with moderate to severe Crohn's disease:The Taiwan Society of Inflammatory Bowel Disease (TSIBD) study","volume":"12","author":"Chang","year":"2014","journal-title":"Intest Res"},{"key":"R290-20250519","first-page":"225","article-title":"Infliximab and adalimumab serum trough concentrations threshold associated with deep remission in inflammatory bowel disease","volume":"45","author":"Pascual-Marmaneu","year":"2021","journal-title":"Farm Hosp"},{"key":"R291-20250519","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/MPG.0000000000002265","article-title":"Adequate infliximab exposure during induction predicts remission in paediatric patients with inflammatory bowel disease","volume":"68","author":"van Hoeve","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R292-20250519","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cgh.2023.08.021","article-title":"Comparative effectiveness of upadacitinib vs ustekinumab for ulcerative colitis: A multicenter retrospective cohort study","volume":"22","author":"Dalal","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R293-20250519","doi-asserted-by":"crossref","first-page":"e15481","DOI":"10.1111\/dth.15481","article-title":"Comparative effectiveness of adalimumab versus ustekinumab in the treatment of severe chronic plaque psoriasis:The results based on data from the program \u201ctreatment of moderate and severe forms of plaque psoriasis (B.47)\u201dof the National Health Fund in Poland","volume":"35","author":"Owczarek","year":"2022","journal-title":"Dermatol Ther"},{"key":"R294-20250519","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/ibd\/izac167","article-title":"Comparative effectiveness of ustekinumab and anti-TNF agent as first-line biological therapy in luminal Crohn's disease: A retrospective study from 2 referral centers","volume":"29","author":"Rivi\u00e8re","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"R295-20250519","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/apt.16057","article-title":"Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease","volume":"52","author":"Townsend","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"R296-20250519","first-page":"CD000301","article-title":"Corticosteroids for maintenance of remission in Crohn's disease","author":"Steinhart","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"R297-20250519","first-page":"CD006792","article-title":"Traditional corticosteroids for induction of remission in Crohn's disease","volume":"2008","author":"Benchimol","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"R298-20250519","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00000658-199804000-00007","article-title":"Comparison of primary and reoperative surgery in patients with Crohns disease","volume":"227","author":"Heimann","year":"1998","journal-title":"Ann Surg"},{"key":"R299-20250519","doi-asserted-by":"crossref","first-page":"347","DOI":"10.36290\/vnl.2018.052","article-title":"Impact of surgery on quality of life in Crohn\u00b4s disease patients: Final results of Czech cohort","volume":"64","author":"Kunovsk\u00fd","year":"2018","journal-title":"Vnitr Lek"},{"key":"R300-20250519","first-page":"259","article-title":"[Effectiveness of mucosal advancement flaps in surgery of perianal fistulas from Crohn\u00b4s disease and cryptoglandular fistulas - A long-term follow-up study]","volume":"148","author":"Schineis","year":"2023","journal-title":"Zentralbl Chir"},{"key":"R301-20250519","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1586\/egh.09.13","article-title":"Infliximab prevents Crohn's disease recurrence after ileal resection","volume":"3","author":"Cottone","year":"2009","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R302-20250519","doi-asserted-by":"crossref","first-page":"204062231983844","DOI":"10.1177\/2040622319838443","article-title":"Infliximab in inflammatory bowel disease","volume":"10","author":"Papamichael","year":"2019","journal-title":"Ther Adv Chronic Dis"},{"key":"R303-20250519","first-page":"CD012328","article-title":"Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease","volume":"2020","author":"Candia","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"R304-20250519","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/jpn3.12179","article-title":"Combination biologic therapy in pediatric inflammatory bowel disease:Safety and efficacy over a minimum 12-month follow-up period","volume":"9","author":"Wlazlo","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R305-20250519","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.gastro.2013.11.024","article-title":"Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease","volume":"146","author":"Feagan","year":"2014","journal-title":"Gastroenterology"},{"key":"R306-20250519","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ecco-jcc\/jjz030","article-title":"Concerns and side effects of azathioprine during adalimumab induction and maintenance therapy for Japanese patients with Crohn's disease:A subanalysis of a prospective randomised clinical trial [DIAMOND Study","volume":"13","author":"Hisamatsu","year":"2019","journal-title":"J Crohns Colitis"},{"key":"R307-20250519","doi-asserted-by":"crossref","first-page":"279","DOI":"10.21037\/atm.2018.06.30","article-title":"DIAMOND study:An additional evidence of the interest of being proactive in IBD","volume":"6","author":"Roblin","year":"2018","journal-title":"Ann Transl Med"},{"key":"R308-20250519","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.gastro.2012.04.046","article-title":"Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children","volume":"143","author":"Hyams","year":"2012","journal-title":"Gastroenterology"},{"key":"R309-20250519","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/ibd.20845","article-title":"Long-term outcome of maintenance infliximab therapy in children with Crohn's disease","volume":"15","author":"Hyams","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"R310-20250519","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/jpc.15528","article-title":"Ustekinumab dose intensification in paediatric Crohn's disease","volume":"57","author":"Rodr\u00edguez-Mauriz","year":"2021","journal-title":"J Paediatr Child Health"},{"key":"R311-20250519","doi-asserted-by":"crossref","first-page":"316","DOI":"10.12688\/f1000research.22673.2","article-title":"Augmented ustekinumab dosing is needed to achieve clinical response in patients with anti-TNF refractory pediatric Crohn's disease: A retrospective chart review","volume":"9","author":"Do","year":"2021","journal-title":"F1000Res"},{"key":"R312-20250519","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1053\/j.gastro.2018.01.043","article-title":"Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn's disease","volume":"154","author":"Adedokun","year":"2018","journal-title":"Gastroenterology"},{"key":"R313-20250519","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.2147\/DDDT.S102141","article-title":"Ustekinumab in treatment of Crohn's disease:Design, development, and potential place in therapy","volume":"10","author":"Deepak","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"R314-20250519","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/2040622318781760","article-title":"Ustekinumab in psoriatic arthritis and related phenotypes","volume":"9","author":"Dobbin-Sears","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"key":"R315-20250519","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"R316-20250519","doi-asserted-by":"crossref","first-page":"640813","DOI":"10.3389\/fmed.2021.640813","article-title":"How to optimize treatment with ustekinumab in inflammatory bowel disease:Lessons learned from clinical trials and real-world data","volume":"8","author":"Guti\u00e9rrez","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R317-20250519","doi-asserted-by":"crossref","first-page":"475","DOI":"10.5217\/ir.2017.15.4.475","article-title":"Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease:A subpopulation analysis of phase 3 induction and maintenance studies","volume":"15","author":"Hibi","year":"2017","journal-title":"Intest Res"},{"key":"R318-20250519","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2217\/cer-2017-0022","article-title":"Efficacy and safety of ustekinumab in the induction therapy of TNF-a-refractory Crohn's disease patients:A systematic review and meta-analysis","volume":"6","author":"Kawalec","year":"2017","journal-title":"J Comp Eff Res"},{"key":"R319-20250519","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ueg2.12094","article-title":"The impact of ustekinumab on extraintestinal manifestations of Crohn's disease:A post hoc analysis of the UNITI studies","volume":"9","author":"Narula","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"R320-20250519","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12876-022-02280-3","article-title":"Long-term effectiveness and safety of ustekinumab in bio-na\u00efve and bio-experienced anti-tumor necrosis factor patients with Crohn's disease: A real-world multicenter Brazilian study","volume":"22","author":"Parra","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"R321-20250519","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/apt.14794","article-title":"Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy","volume":"48","author":"Sandborn","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"R322-20250519","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/ecco-jcc\/jjy055","article-title":"The effects of ustekinumab on health-related quality of life in patients with moderate to severe Crohn's disease","volume":"12","author":"Sands","year":"2018","journal-title":"J Crohns Colitis"},{"key":"R323-20250519","doi-asserted-by":"crossref","first-page":"e193721","DOI":"10.1001\/jamanetworkopen.2019.3721","article-title":"Development and validation of machine learning models in prediction of remission in patients with moderate to severe Crohn disease","volume":"2","author":"Waljee","year":"2019","journal-title":"JAMA Netw Open"},{"key":"R324-20250519","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/ibd\/izac231","article-title":"Predictors of clinical remission to placebo in clinical trials of Crohn's disease","volume":"29","author":"Wong","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"R325-20250519","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/MPG.0000000000002362","article-title":"Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center","volume":"69","author":"Dayan","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R326-20250519","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/ecco-jcc\/jjx082","article-title":"Vedolizumab in paediatric inflammatory bowel disease: A retrospective multi-centre experience from the paediatric IBD porto group of ESPGHAN","volume":"11","author":"Ledder","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R327-20250519","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2468-1253(22)00307-7","article-title":"Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS):A prospective, multicentre cohort study","volume":"8","author":"Atia","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R328-20250519","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/jhn.12386","article-title":"British Dietetic Association systematic review of systematic reviews and evidence-based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016 update)","volume":"29","author":"McKenzie","year":"2016","journal-title":"J Hum Nutr Diet"},{"key":"R329-20250519","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/nu3020245","article-title":"Probiotics in inflammatory bowel diseases and associated conditions","volume":"3","author":"Mack","year":"2011","journal-title":"Nutrients"},{"key":"R330-20250519","first-page":"CD006634","article-title":"Probiotics for induction of remission in Crohn's disease","volume":"16","author":"Butterworth","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"R331-20250519","first-page":"31","article-title":"Update on fecal microbiota transplantation for the treatment of inflammatory bowel disease","volume":"17","author":"Allegretti","year":"2021","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"R332-20250519","doi-asserted-by":"crossref","first-page":"574533","DOI":"10.3389\/fphar.2020.574533","article-title":"Fecal microbiota transplantation for the treatment of inflammatory bowel disease:An update","volume":"11","author":"Tan","year":"2020","journal-title":"Front Pharmacol"},{"key":"R333-20250519","doi-asserted-by":"crossref","first-page":"175628482311562","DOI":"10.1177\/17562848231156285","article-title":"Short- and long-term follow-up after fecal microbiota transplantation as treatment for recurrent Clostridioides difficile infection in patients with inflammatory bowel disease","volume":"16","author":"van Lingen","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"R334-20250519","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/jgh.15731","article-title":"An update on fecal microbiota transplantation for the treatment of gastrointestinal diseases","volume":"37","author":"Waller","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"R335-20250519","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12934-023-02027-z","article-title":"Fecal microbiota transplantation attenuates Escherichia coli infected outgrowth by modulating the intestinal microbiome","volume":"22","author":"Wang","year":"2023","journal-title":"Microb Cell Fact"},{"key":"R336-20250519","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/MEG.0000000000002519","article-title":"A systematic review, pairwise meta-analysis and network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in irritable bowel syndrome","volume":"35","author":"Rokkas","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R337-20250519","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2468-1253(17)30252-2","article-title":"Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT):A multicentre inception cohort study","volume":"2","author":"Hyams","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R338-20250519","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/children10010011","article-title":"Dual biologic therapy in moderate to severe pediatric inflammatory bowel disease: A retrospective study","volume":"10","author":"Wlaz\u0142o","year":"2022","journal-title":"Children"},{"key":"R339-20250519","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/MPG.0b013e31826ac41a","article-title":"Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis","volume":"56","author":"Zeisler","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R340-20250519","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/MPG.0000000000000530","article-title":"High- and low-dose oral delayed-release mesalamine in children with mild-to-moderately active ulcerative colitis","volume":"59","author":"Winter","year":"2014","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R341-20250519","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1177\/2050640619864257","article-title":"Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience","volume":"7","author":"Maconi","year":"2019","journal-title":"United European Gastroenterol J."},{"key":"R342-20250519","doi-asserted-by":"crossref","first-page":"e000092","DOI":"10.1136\/bmjgast-2016-000092","article-title":"Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis:Study protocol for a prospective multicentre observational cohort study","volume":"3","author":"Danese","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"key":"R343-20250519","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/gutjnl-2012-304258","article-title":"Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis:Results from the randomised CORE II study","volume":"63","author":"Travis","year":"2014","journal-title":"Gut"},{"key":"R344-20250519","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.3748\/wjg.v19.i11.1699","article-title":"Thiopurines in inflammatory bowel disease revisited","volume":"19","author":"B\u00e4r","year":"2013","journal-title":"World J Gastroenterol"},{"key":"R345-20250519","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.3390\/jcm10194329","article-title":"Comparative outcomes of budesonide MMX versus prednisolone for ulcerative colitis: Results from a British retrospective multi-centre real-world study","volume":"10","author":"Rosiou","year":"2021","journal-title":"J Clin Med"},{"key":"R346-20250519","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/MPG.0000000000002091","article-title":"Switching from originator to biosimilar infliximab in paediatric inflammatory bowel disease is feasible and uneventful","volume":"67","author":"Gervais","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R347-20250519","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/ecco-jcc\/jjaa201","article-title":"Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 [PIMS-TS] in a patient receiving infliximab therapy for inflammatory bowel disease","volume":"15","author":"Meredith","year":"2021","journal-title":"J Crohns Colitis"},{"key":"R348-20250519","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/ecco-jcc\/jjv233","article-title":"switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations","volume":"10","author":"Sieczkowska","year":"2016","journal-title":"J Crohns Colitis"},{"key":"R349-20250519","first-page":"151","article-title":"Infliximab:The evidence for its place in therapy in ulcerative colitis","volume":"2","author":"Van Assche","year":"2008","journal-title":"Core Evid"},{"key":"R350-20250519","doi-asserted-by":"crossref","first-page":"6699","DOI":"10.3390\/jcm12206699","article-title":"Efficacy of switching to adalimumab for maintenance of remission following induction therapy with tacrolimus in patients with ulcerative colitis","volume":"12","author":"Numa","year":"2023","journal-title":"J Clin Med"},{"key":"R351-20250519","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/apt.12145","article-title":"One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab:Subgroup analyses from ULTRA 2","volume":"37","author":"Sandborn","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R352-20250519","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1365-2036.2010.04531.x","article-title":"Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab","volume":"33","author":"Taxonera","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R353-20250519","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S2468-1253(21)00142-4","article-title":"Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I):A randomised, controlled, phase 3 study","volume":"6","author":"Croft","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R354-20250519","first-page":"CD000545","article-title":"Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease","author":"Chande","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R355-20250519","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5217\/ir.2020.00155","article-title":"Use of thiopurines in inflammatory bowel disease:An update","volume":"20","author":"Singh","year":"2022","journal-title":"Intest Res"},{"key":"R356-20250519","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1346-8138.2010.01005.x","article-title":"Azathioprine-induced pure red cell aplasia in a systemic sclerosis patient with interstitial pneumonia","volume":"38","author":"Suto","year":"2011","journal-title":"J Dermatol"},{"key":"R357-20250519","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med"},{"key":"R358-20250519","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.cgh.2015.04.010","article-title":"Concomitant use of immunomodulators affects the durability of infliximab therapy in children with Crohn's disease","volume":"13","author":"Grossi","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R359-20250519","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/gut.2004.060103","article-title":"Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild\/moderate active ulcerative colitis:A randomised, double blind, placebo controlled study","volume":"54","author":"Marteau","year":"2005","journal-title":"Gut"},{"key":"R360-20250519","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0009-9120(00)00175-2","article-title":"New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine","volume":"34","author":"Armstrong","year":"2001","journal-title":"Clin Biochem"},{"key":"R361-20250519","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.dld.2011.10.004","article-title":"Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids","volume":"44","author":"Garcia-Planella","year":"2012","journal-title":"Dig Liver Dis"},{"key":"R362-20250519","first-page":"612","article-title":"Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn's disease and ulcerative colitis","volume":"34","author":"Hashash","year":"2021","journal-title":"Ann Gastroenterol"},{"key":"R363-20250519","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/apt.14030","article-title":"Systematic review with meta-analysis:Comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials","volume":"45","author":"Cholapranee","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R364-20250519","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"R365-20250519","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/ecco-jcc\/jjz019","article-title":"Intensified infliximab induction is associated with improved response and decreased colectomy in steroid-refractory paediatric ulcerative colitis","volume":"13","author":"Church","year":"2019","journal-title":"J Crohns Colitis"},{"key":"R366-20250519","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12876-018-0868-x","article-title":"Vedolizumab use after failure of TNF-a antagonists in children and adolescents with inflammatory bowel disease","volume":"18","author":"Schneider","year":"2018","journal-title":"BMC Gastroenterol"},{"key":"R367-20250519","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/j.gastro.2018.11.039","article-title":"Thiopurine therapy in inflammatory bowel diseases:Making new friends should not mean losing old ones","volume":"156","author":"de Boer","year":"2019","journal-title":"Gastroenterology"},{"key":"R368-20250519","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/ecco-jcc\/jjx166","article-title":"Combination therapy with adalimumab and thiopurines in inflammatory bowel disease:Is it a case of nepotism in pharmacology?","volume":"12","author":"AlAmeel","year":"2018","journal-title":"J Crohns Colitis"},{"key":"R369-20250519","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/MIB.0000000000001183","article-title":"Thiopurines dosed to a therapeutic 6-thioguanine level in combination with adalimumab are more effective than subtherapeutic thiopurine-based combination therapy or adalimumab monotherapy during induction and maintenance in patients with long-standing crohn's disease","volume":"23","author":"Kariyawasam","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"R372-20250519","first-page":"249","article-title":"Vaccination recommendations for psoriasis and atopic dermatitis patients on biologic therapy:A practical guide","volume":"95","author":"Fan","year":"2022","journal-title":"Yale J Biol Med"},{"key":"R373-20250519","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00535-022-01953-w","article-title":"Expert consensus on vaccination in patients with inflammatory bowel disease in Japan","volume":"58","author":"Ishige","year":"2023","journal-title":"J Gastroenterol"},{"key":"R374-20250519","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3390\/vaccines9050487","article-title":"Vaccines in children with inflammatory bowel disease: Brief review","volume":"9","author":"Esposito","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"R375-20250519","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1440-1746.1995.tb01108.x","article-title":"Immunizations in children with inflammatory bowel disease treated with immunosuppressive therapy","volume":"10","author":"Lu","year":"2014","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"R376-20250519","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/14760584.2021.1875825","article-title":"Immune response and safety of viral vaccines in children with autoimmune diseases on immune modulatory drug therapy","volume":"19","author":"Tse","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"R377-20250519","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40257-015-0124-x","article-title":"Screening and vaccinations in patients requiring systemic immunosuppression:An update for dermatologists","volume":"16","author":"Goyal","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"R378-20250519","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1055\/s-2005-858972","article-title":"Maintaining remission of ulcerative colitis with the probiotic escherichia coli Nissle 1917 is as effective as with standard Mesalazine","volume":"44","author":"Adam","year":"2006","journal-title":"Z Gastroenterol"},{"key":"R379-20250519","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/gut.2003.037747","article-title":"Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine","volume":"53","author":"Kruis","year":"2004","journal-title":"Gut"},{"key":"R380-20250519","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4166\/kjg.2012.60.2.94","article-title":"Effect of a probiotic preparation (VSL#3) in patients with mild to moderate ulcerative colitis","volume":"60","author":"Lee","year":"2012","journal-title":"Korean J Gastroenterol"},{"issue":"(Suppl 3)","key":"R381-20250519","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1097\/MCG.0b013e31815f5ac7","article-title":"Balsalazide plus high-potency probiotic preparation (VSL.3) in the treatment of acute mild-to-moderate ulcerative colitis and uncomplicated diverticulitis of the colon","volume":"42","author":"Tursi","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"R382-20250519","first-page":"PI126","article-title":"Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis","volume":"10","author":"Tursi","year":"2004","journal-title":"Med Sci Monit"},{"key":"R383-20250519","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1097\/MIB.0000000000000084","article-title":"Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis","volume":"20","author":"Mardini","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"R384-20250519","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.cgh.2009.05.031","article-title":"Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection","volume":"7","author":"Ben-Horin","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R385-20250519","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3748\/wjg.v22.i3.1078","article-title":"Role of antibiotics for treatment of inflammatory bowel disease","volume":"22","author":"Nitzan","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R386-20250519","first-page":"543","article-title":"Efficacy and safety of fecal microbiota transplant for recurrent clostridium difficile infection in inflammatory bowel disease patients:A systematic review and meta-analysis","volume":"114","author":"Cheng","year":"2022","journal-title":"Rev Esp Enferm Dig"},{"key":"R387-20250519","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/MPG.0000000000002172","article-title":"Fecal microbiota transplant for recurrent clostridium difficile infection in pediatric inflammatory bowel disease","volume":"68","author":"Cho","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R388-20250519","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/ibd\/izx035","article-title":"Safety, clinical response, and microbiome findings following fecal microbiota transplant in children with inflammatory bowel disease","volume":"24","author":"Goyal","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"R389-20250519","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/jpn3.12132","article-title":"Proactive therapeutic drug monitoring and vedolizumab dose optimization in children with inflammatory bowel disease","volume":"78","author":"Rowland","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R390-20250519","doi-asserted-by":"crossref","first-page":"445","DOI":"10.36849\/JDD.6671","article-title":"Anti-tumor necrosis factor alpha therapeutic drug monitoring in inflammatory disease:A systematic review","volume":"22","author":"Schneider","year":"2023","journal-title":"J Drugs Dermatol"},{"key":"R391-20250519","first-page":"435","article-title":"Impact of proactive therapeutic drug monitoring of infliximab during the induction phase in IBD patients. A Bayesian approach","volume":"115","author":"Serrano-D\u00edaz","year":"2023","journal-title":"Rev Esp Enferm Dig"},{"key":"R392-20250519","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/apt.17313","article-title":"Meta-analysis:The efficacy of therapeutic drug monitoring of anti- TNF -therapy in inflammatory bowel disease","volume":"57","author":"Sethi","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"R393-20250519","doi-asserted-by":"crossref","first-page":"972","DOI":"10.3390\/pharmaceutics15030972","article-title":"Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease patients during maintenance treatment\u2014TUMMY study","volume":"15","author":"Sivrida\u015f","year":"2023","journal-title":"Pharmaceutics"},{"key":"R394-20250519","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/00365521.2023.2176252","article-title":"Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring","volume":"58","author":"Wiken","year":"2023","journal-title":"Scand J Gastroenterol"},{"key":"R395-20250519","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s12664-024-01527-z","article-title":"Therapeutic drug monitoring in inflammatory bowel disease: A practical approach","volume":"43","author":"Desai","year":"2024","journal-title":"Indian J Gastroenterol"},{"key":"R396-20250519","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3390\/medicina60020250","article-title":"Therapeutic drug monitoring for biologic and small-molecule therapies for inflammatory bowel disease","volume":"60","author":"Dutt","year":"2024","journal-title":"Medicina (B Aires)"},{"key":"R397-20250519","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.3390\/biomedicines11061757","article-title":"Efficacy of early optimization of infliximab guided by therapeutic drug monitoring during induction\u2014 A prospective trial","volume":"11","author":"Garcia","year":"2023","journal-title":"Biomedicines"},{"key":"R398-20250519","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.gastrohep.2022.10.019","article-title":"Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease","volume":"46","author":"D\u00edaz","year":"2023","journal-title":"Gastroenterol Hepatol"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_171_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:50:24Z","timestamp":1787773824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_171_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":392,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/sjg.sjg_171_24","relation":{},"ISSN":["1319-3767","1998-4049"],"issn-type":[{"value":"1319-3767","type":"print"},{"value":"1998-4049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"2024-05-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}